{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:26:58Z","timestamp":1755221218673,"version":"3.43.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Adeno-associated virus (AAV)-mediated gene therapy is a promising approach to treat genetic disorders, offering advantages such as high transduction efficiency, diverse tissue tropism, and an acceptable safety profile. However, the immunogenicity of AAV vectors, particularly the activation of AAV capsid-specific CD8 T cells, significantly impacts therapeutic efficacy and safety. Capsid-specific T cell responses are currently monitored in the clinic using overlapping peptides, which do not represent the naturally presented capsid immunopeptidome. Our previous work identified the naturally presented peptides of AAV capsids using MHC-associated peptide proteomics (MAPPs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we compared overlapping and MAPPs-derived peptides of the AAV9 capsid in their capacity to trigger capsid-specific T cell responses in healthy donor PBMCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both peptide groups induced measurable T cell responses in FluoroSpot assays only after an expansion phase, reflecting the low frequency of circulating capsid-specific T cells in both seropositive and seronegative donors. Surprisingly, overlapping and MAPPs-derived capsid peptides expanded largely distinct T cells that did not cross-react. The T cell response to MAPPs-derived capsid peptides was dominated by capsid-specific CD8 T cells recognizing peptides eluted from HLA Class I, allowing us to identify CD8 T cell capsid epitopes in healthy donors. By screening 13 matrix pools (comprising 41 HLA Class I MAPPs peptides of the AAV9 capsid) in 24 healthy donors using FluoroSpot assays, we identified ten epitopes eliciting IFN-\u03b3 release in at least one donor. 9 of the 10 identified epitopes were novel, varied between 9\u201313 amino acids in length, and displayed strong binding to their predicted HLA binding alleles. Only one of four previously reported capsid CD8 T cell epitopes elicited a response in the tested cohort of healthy donors with diverse HLAs. Remarkably, in two instances where MAPPs peptides of different lengths were presented on HLA Class I, CD8 T cell response was only observed to longer epitopes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our results represent the first extensive analysis of the naturally presented peptides of the AAV9 capsid. This work provides strategies to improve the detection of the capsid-specific CD8 T cell response in the clinic and reduce vector immunogenicity through the identification of novel CD8 T cell epitopes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1641289","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T10:02:00Z","timestamp":1754647320000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Epitope mapping using immunopeptidomics reveals novel immunodominant CD8 T cell epitopes of the AAV9 capsid"],"prefix":"10.3389","volume":"16","author":[{"given":"Akhila","family":"Balasubramanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Prachar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Klaproth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sune","family":"Justesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent P.","family":"Malherbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: A long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B3","volume-title":"FDA approves l-amino acid decarboxylase deficiency gene therapy","author":"Mullard","year":"2024"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/jcm10112471","article-title":"Emerging immunogenicity and genotoxicity considerations of adeno-associated virus vector gene therapy for hemophilia","volume":"10","author":"Monahan","year":"2021","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"key":"B6","volume-title":"Molecular Biology of the Cell","author":"Alberts","year":"2002"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm1549","article-title":"CD8+ T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector\u2013mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00698","article-title":"Applying MAPPs assays to assess drug immunogenicity","volume":"11","author":"Karle","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"108454","DOI":"10.1016\/j.celrep.2020.108454","article-title":"The human leukocyte antigen class II immunopeptidome of the SARS-coV-2 spike glycoprotein","volume":"33","author":"Knierman","year":"2020","journal-title":"Cell Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41467-024-55522-1","article-title":"Rational engineering of minimally immunogenic nucleases for gene therapy","volume":"16","author":"Raghavan","year":"2025","journal-title":"Nat\u00a0Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212136","article-title":"The HLA class I immunopeptidomes of AAV capsid proteins","volume":"14","author":"Brito-Sierra","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1067399","article-title":"The HLA class-II immunopeptidomes of AAV capsids proteins","volume":"13","author":"Brito-Sierra","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"113397","DOI":"10.1016\/j.jim.2022.113397","article-title":"A sensitive and drug tolerant assay for detecting anti-AAV9 antibodies using affinity capture elution","volume":"512","author":"Simmons","year":"2023","journal-title":"J Immunol Methods"},{"key":"B16","doi-asserted-by":"publisher","first-page":"198508","DOI":"10.1016\/j.virusres.2021.198508","article-title":"SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects","volume":"304","author":"Zhao","year":"2021","journal-title":"Virus Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100758","DOI":"10.1016\/j.xpro.2021.100758","article-title":"A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses","volume":"2","author":"Cimen Bozkus","year":"2021","journal-title":"STAR Protoc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20465","DOI":"10.1038\/s41598-020-77466-4","article-title":"Identification and validation of 174 COVID-19 vaccine candidate epitopes reveals low performance of common epitope prediction tools","volume":"10","author":"Prachar","year":"2020","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1745-7580-5-2","article-title":"Functional recombinant MHC class II molecules and high-throughput peptide-binding assays","volume":"5","author":"Justesen","year":"2009","journal-title":"Immunome Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2002.590402.x","article-title":"Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction","volume":"59","author":"Sylvester-Hvid","year":"2002","journal-title":"Tissue Antigens"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/1087057108329453","article-title":"Peptide\u00a0binding to HLA class I molecules: homogenous, high-throughput screening,\u00a0and affinity assays","volume":"14","author":"Harndahl","year":"2009","journal-title":"J Biomol Screen"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094892","article-title":"Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2","volume":"9","author":"Braendstrup","year":"2014","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835454","article-title":"Accurate MHC motif deconvolution of immunopeptidomics data reveals a significant contribution of DRB3, 4 and 5 to the total DR immunopeptidome","volume":"13","author":"Kaabinejadian","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn202","article-title":"NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11","volume":"36","author":"Lundegaard","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122372","article-title":"Exposure to wild-type AAV drives distinct capsid immunity profiles in humans","volume":"128","author":"Kuranda","year":"2018","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15029","DOI":"10.1038\/mtm.2015.29","article-title":"AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes","volume":"2","author":"Hui","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03110","article-title":"Tetramer-based enrichment of preexisting anti-AAV8 CD8(+) T cells in human donors allows the detection of a T(EMRA) subpopulation","volume":"10","author":"Vandamme","year":"2019","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666666","article-title":"T cell-mediated immune responses to AAV and AAV vectors","volume":"12","author":"Ertl","year":"2021","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.9.5907","article-title":"HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals","volume":"180","author":"Calarota","year":"2008","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd3871","article-title":"Selective and\u00a0cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","first-page":"637649","DOI":"10.1155\/2013\/637649","article-title":"Enumeration and characterization of human memory T cells by enzyme-linked immunospot assays","volume":"2013","author":"Calarota","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.01.005","article-title":"Differential T cell immune responses to deamidated adeno-associated virus vector","volume":"24","author":"Bing","year":"2022","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1211529","article-title":"Low cross reactivity between wild type and deamidated AAV can lead to false negative results in immune monitoring T-cell assays","volume":"14","author":"Bing","year":"2023","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200620","article-title":"Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors","volume":"188","author":"Veron","year":"2012","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1208\/s12248-023-00814-5","article-title":"Evaluation of cellular immune response to adeno-associated virus-based gene therapy","volume":"25","author":"Gorovits","year":"2023","journal-title":"AAPS J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-023-01129-8","article-title":"Rational\u00a0immunosilencing of a promiscuous T-cell epitope in the capsid of an adeno-associated virus","volume":"8","author":"Bing","year":"2023","journal-title":"Nat BioMed Eng"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.166","article-title":"Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes","volume":"21","author":"Hui","year":"2013","journal-title":"Mol Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36891","article-title":"Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors","volume":"119","author":"Pien","year":"2009","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.10.006","article-title":"Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF","volume":"13","author":"Chen","year":"2006","journal-title":"IX Gene Ther Mol Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.immuni.2021.04.009","article-title":"CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity","volume":"54","author":"Nguyen","year":"2021","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.607028","article-title":"Naturally processed non-canonical HLA-A*02:01 presented peptides","volume":"290","author":"Hassan","year":"2015","journal-title":"J Biol Chem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.09.026","article-title":"Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition","volume":"45","author":"Burrows","year":"2008","journal-title":"Mol Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425193","article-title":"Potent T\u2004cell response to a class I-binding 13-mer viral epitope and the influence of HLA micropolymorphism in controlling epitope length","volume":"34","author":"Green","year":"2004","journal-title":"Eur J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/s41467-018-03321-w","article-title":"Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide","volume":"9","author":"Chan","year":"2018","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300292","article-title":"HLA peptide length preferences control CD8+ T cell responses","volume":"191","author":"Rist","year":"2013","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1038\/s41467-021-25414-9","article-title":"Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4(+) T-cells","volume":"12","author":"Simhadri","year":"2021","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells","volume":"121","author":"Martino","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1641289\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T10:02:02Z","timestamp":1754647322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1641289\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2025.1641289"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1641289","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"1641289"}}